Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect Jun 07, 2021 10:30am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Jun 04, 2021 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 14, 2021 4:01pm EDT
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit May 13, 2021 4:01pm EDT
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer May 10, 2021 8:30am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 07, 2021 4:01pm EDT
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress May 04, 2021 4:01pm EDT
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Apr 27, 2021 5:51pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Apr 02, 2021 4:35pm EDT
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Mar 14, 2021 4:00pm EDT
